导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.01% | 3172/4773 |
| 近一周 | -1.31% | 2002/5465 |
| 近一月 | -1.33% | 1116/5421 |
| 近一季 | -0.09% | 1012/5231 |
| 近半年 | -0.67% | 1547/4920 |
| 近一年 | 0.58% | 2667/4394 |
| 近两年 | 37.78% | 1997/2954 |
| 近三年 | 24.49% | 1320/2253 |
| 成立以来 | 35.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.56% 4161/4961 |
6.96% 2774/5312 |
- - |
- - |
| 2025 | 16.58% 2440/4813 |
-0.55% 2297/3635 |
3.02% 1202/4076 |
11.33% 3177/4524 |
2.20% 1045/4813 |
| 2024 | 18.56% 592/3463 |
3.65% 528/2808 |
-0.07% 676/3014 |
17.38% 1204/3129 |
-2.48% 2103/3463 |
| 2023 | -8.52% 1021/2656 |
0.90% 1675/2280 |
-4.46% 1177/2385 |
1.90% 268/2515 |
-6.87% 1951/2655 |
| 2022 | -16.68% 502/2207 |
-11.39% 505/1919 |
6.96% 568/2016 |
-13.42% 900/2113 |
1.54% 1229/2208 |
| 2021 | -5.23% 972/1822 |
-2.59% 672/1255 |
1.72% 1036/1330 |
-6.64% 970/1466 |
2.45% 593/1822 |
| 2020 | 31.68% 497/1250 |
-10.36% 773/1028 |
12.71% 672/1067 |
14.66% 268/1164 |
13.68% 340/1184 |
| 2019 | - - |
- - |
- - |
- - |
6.08% 658/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达上证50ETF VS. 长安沪深300非周期A(740101) |